# Genentech's KRAS G12C Inhibitor Divarasib Posts Superior Phase 3 Results in NSCLC

> clinical trial · REPORTED · 2026-07-03

Roche's Genentech unit reported that divarasib, its KRAS G12C inhibitor, achieved superior Phase 3 results over approved therapies in previously treated non-small-cell lung cancer patients, as reported by BioWorld on July 3, 2026. The data strengthen divarasib's position as a potential best-in-class treatment in the competitive KRAS G12C inhibitor market.

- Company: Genentech / Roche
- Sector: oncology
- Primary source: https://www.bioworld.com/topics/84-bioworld

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.